← Back to all trials
Recruiting
NCT07577661
Combination Upper-Airway Electrical and Pharmacological Stimulation for Obstructive Sleep Apnea
Conditions: Obstructive Sleep Apnea, Sleep-disordered Breathing
Sex: All
Ages: 18 Years – 79 Years
Healthy volunteers: No
Phase: PHASE1, PHASE2
Enrollment: 24
Sponsor: Brigham and Women's Hospital
Location: Brigham and Women's Hospital Boston Massachusetts
Summary
Obstructive sleep apnea (OSA) is a common condition in which the airway repeatedly collapses during sleep, leading to poor sleep quality and reduced oxygen levels. Hypoglossal nerve stimulation (HGNS) is an approved treatment that uses a small implanted device to stimulate the genioglossus muscle and keep the airway open. However, some patients continue to have OSA despite using HGNS. Atomoxetine and oxybutynin, "AtoOxy", is a promising pharmacologcal therapy under investigation that has been shown to activate pharyngeal muscles-in particular non-genioglossus muscles--but appears more efficacious in some patients than others.
This study will test whether the combination of AtoOxy and HGNS can further improve breathing during sleep compared to either monotherapy alone. Participants with OSA and an HGNS device will be randomized to receive, in random order: HGNS+AtoOxy, HGNS alone (plus placebo), AtoOxy alone (HGNS device off), and placebo (HGNS device off), in a cross-over trial.
The main goal is to determine whether the combined treatment reduces the number of breathing events during sleep; the primary outcome test will compare HGNS+AtoOxy versus HGNS alone. The effect of each intervention versus placebo will also be presented.
The study will also examine how individual patient characteristics influence response to treatment.
Eligibility Criteria
Inclusion Criteria for Enrolment:
* Ages 18 - 79 years
* Diagnosed OSA
* Implantation of a hypoglossal nerve stimulation device (HGNS, Inspire Medical) or scheduled for implantation (implantation required for randomization)
* Willingness to withhold HGNS while testing therapies (up to 6 weeks with HGNS off \[with/without pharmacotherapy\] to assess benefits of HGNS therapy).
Exclusion Criteria:
* Any uncontrolled medical condition
* Current use of the medications under investigation.
* Issues relating to short-term withdrawal of HGNS therapy
* Excluded: Occupational driving (truck drivers, fork-lift operation, taxi/uber drivers)
* Excluded: History of traffic accidents attributable to sleepiness or fatigue (\
Source: ClinicalTrials.gov (NCT07577661). StuddyBuddy aggregates publicly available trial information.